Citigroup Inc Vera Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 29,404 shares of VERA stock, worth $981,211. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,404

Previous 21,282 38.16%

Holding current value

$981,211

Previous $769,000 68.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$34.09 - $46.71 $276,878 - $379,378	8,122 Added 38.16%	29,404 $1.3 Million
Q2 2024 Aug 12, 2024	SELL	$33.72 - $48.82 $4.43 Million - $6.41 Million	-131,286 Reduced 86.05%	21,282 $769,000
Q1 2024 May 10, 2024	BUY	$14.91 - $49.14 $1.23 Million - $4.04 Million	82,263 Added 117.01%	152,568 $6.58 Million
Q4 2023 Feb 09, 2024	BUY	$9.29 - $16.0 $119,980 - $206,640	12,915 Added 22.5%	70,305 $1.08 Million
Q3 2023 Nov 09, 2023	BUY	$13.71 - $19.64 $648,784 - $929,404	47,322 Added 470.02%	57,390 $786,000
Q2 2023 Aug 10, 2023	BUY	$6.11 - $17.83 $61,515 - $179,512	10,068 New	10,068 $161,000
Q4 2022 Feb 09, 2023	SELL	$15.74 - $22.19 $12,324 - $17,374	-783 Reduced 62.64%	467 $9,000
Q3 2022 Nov 10, 2022	SELL	$13.27 - $22.31 $132,434 - $222,653	-9,980 Reduced 88.87%	1,250 $27,000
Q2 2022 Aug 10, 2022	BUY	$12.82 - $23.4 $4,294 - $7,838	335 Added 3.07%	11,230 $153,000
Q1 2022 May 12, 2022	BUY	$17.8 - $28.06 $146,636 - $231,158	8,238 Added 310.05%	10,895 $256,000
Q4 2021 Feb 10, 2022	BUY	$15.01 - $35.8 $27,723 - $66,122	1,847 Added 228.02%	2,657 $71,000
Q3 2021 Nov 10, 2021	BUY	$13.71 - $30.6 $11,105 - $24,786	810 New	810 $14,000

Others Institutions Holding VERA

# of Institutions

185

Shares Held

55.2M

Call Options Held

134K

Put Options Held

156K

View Full List

About Vera Therapeutics, Inc.

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $902M
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

More about VERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account